Log in
Enquire now
Kallyope

Kallyope

Kallyope is a New York City, New York based biotechnology company founded in 2015 developing therapeutics to improve human health by better understanding the gut-brain relationship.

OverviewStructured DataIssuesContributors

Contents

kallyope.com
Is a
Organization
Organization
Company
Company

Company attributes

Industry
‌
Pharmaceuticals
Healthcare
Healthcare
Technology
Technology
Biology
Biology
Biotechnology
Biotechnology
Location
New York
New York
New York City
New York City
B2X
B2B
B2B
CEO
‌
Jay Galeota
0
Founder
Tom Maniatis
Tom Maniatis
0
Charles Zuker
Charles Zuker
0
Richard Axel
Richard Axel
0
Pitchbook URL
pitchbook.com/profiles...149119-93
Legal Name
Kallyope Inc.
Legal classification
Incorporation (business)
Incorporation (business)
Corporation
Corporation
Date Incorporated
2014
Spun Out From
Columbia University
Columbia University
Number of Employees (Ranges)
51 – 200
Email Address
info@kallyope.com
Full Address
430 E 29TH St Ste 850 New York​, NY, 10016-8367 United States
CIK Number
1,655,846
Investors
‌
Euclidean Capital
Alexandria Venture Investments
Alexandria Venture Investments
The Column Group
The Column Group
The Column Group
The Column Group
‌
Anthony Evnin
StepStone Group
StepStone Group
Casdin Capital
Casdin Capital
Tao Capital Partners
Tao Capital Partners
...
Founded Date
January 1, 2015
Total Funding Amount (USD)
523,050,000
Latest Funding Round Date
February 15, 2022
Former CEO
Nancy Thornberry
Nancy Thornberry
Latest Funding Type
Series D
Series D
Patents Assigned (Count)
1
Country
United States
United States
Headquarters
New York City
New York City

Other attributes

Company Operating Status
Active
Latest Funding Round Amount (USD)
236,000,000
Wikidata ID
Q107518437

Kallyope is a biotechnology and therapeutic microbiome company that was founded by Charles Zucker, Tom Maniatis, and Richard Axel in 2015 that is headquartered in New York City, New York. Kallyope uses gene sequencing, computational biology, neural imaging, cellular/molecular biology, and human genetics to understand the relationship between the human gut and the human brain in combination with their own drug discovery expertise to develop effective gut-brain therapies that improve human health and nutrition.

Funding
Series A

On December 10, 2015 Kallyope closed their series A funding round with $44 million in funding from The Column Group, Polaris Partners, Lux Capital, Illumina Ventures, Alexandria Venture investments, and Tony Evnin.

Series B

On February 22, 2018 Kallyope closed their series B funding round with $66 million in funding from Two Sigma Ventures, The Column Group, Polaris Partners, Lux Capital, Illumina Ventures, Euclidean Capital, and Alexandria Venture Investments.

Timeline

No Timeline data yet.

Funding Rounds

Products

Acquisitions

SBIR/STTR Awards

Patents

Further Resources

Title
Author
Link
Type
Date

Kallyope and Novo Nordisk Team Up To Tackle Obesity | BioSpace

Mark Terry

https://www.biospace.com/article/kallyope-and-novo-nordisk-team-up-to-tackle-obesity/

Web

References

Find more companies like Kallyope

Use the Golden Query Tool to find similar companies in the same industry, location, or by any other field in the Knowledge Graph.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.